Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 5/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.44 |
| ▸ | THRB | P10828 | 3/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10290862 | 0.90 | ACVR1 (0.48) | ACVR1MAPK14MAPK10MAPK9PDE4B | |
| SCHEMBL3107492 | 0.90 | ACVR1 (0.48) | ACVR1MAPK14MAPK10MAPK9PDE4B | |
| SCHEMBL3094572 | 0.90 | MAPK14 (0.52) | ACVR1MAPK14MAPK9MAPK13MAPK12 | |
| SCHEMBL3094899 | 0.85 | ACVR1 (0.58) | ACVR1MAPK14MAPK10MAPK9PDE4B | |
| SCHEMBL3110798 | 0.84 | MAPK10 (0.55) | ACVR1MAPK14MAPK10MAPK9MAPK13 | |
| SCHEMBL3112056 | 0.81 | MAPK14 (0.51) | ACVR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL28428298 | 0.79 | ACVR1 (0.45) | ACVR1MAPK14THRBTGFBR1 | |
| SCHEMBL10290368 | 0.79 | CSNK1D (0.53) | ACVR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2523383 | 0.77 | TGFBR1 (0.46) | MAPK14MAPK10MAPK13MAPK12MAPK11 | |
| SCHEMBL10290363 | 0.76 | CSNK1D (0.51) | ACVR1MAPK14MAPK10MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217600-B1 | FUNGICIDAL BICYCLIC PYRAZOLES | DU PONT (US) | 2012-12-05 | — | — | EP | claimed |
| US-20100273775-A1 | FUNGICIDAL BICYCLIC PYRAZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-10-28 | — | — | US | claimed |
| EP-2217600-B1 | FUNGICIDAL BICYCLIC PYRAZOLES | DU PONT (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8288375-B2 | Fungicidal bicyclic pyrazoles | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2409570-A2 | Fungicidal mixtures based on pyrazolopyridine compounds | BASF SE (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-20100273775-A1 | FUNGICIDAL BICYCLIC PYRAZOLES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273775-A1 | FUNGICIDAL BICYCLIC PYRAZOLES | CYP1B1, CBR1, CYP1A1 | ACVR1 3435/4885MAPK14 3609/4885MAPK10 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.